---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-093007"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2025-07-02T23:59:59+00:00"
generated_at: "2026-05-18T09:51:11.807750+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Shareholders approve 19.5M share increase to 2021 Equity Plan at annual meeting

## Summary
- Shareholders approved amendment increasing common shares reserved under 2021 Equity Plan by 19,500,000.
- All seven director nominees elected: Mulroy, Amin, Andrews, Russell, Bradsher, Culley, Jayasuriya.
- Ratification of Baker Tilly as auditor for FY2025 received ~159M votes for, ~912K against.
- Advisory say-on-pay approved with ~96M votes for, ~3.8M against, ~612K abstentions.
- EIP Amendment approved with ~88.6M for, ~11.6M against, ~351K abstentions.

## SEC filing metadata
- accession: 0000950170-25-093007
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2025-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000095017025093007/0000950170-25-093007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000095017025093007/lctx-20250626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-093007
- JSON: https://secwatch.observer/filing/0000950170-25-093007.json
- Plain text: https://secwatch.observer/filing/0000950170-25-093007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.